SUMMARY
INTRODUCTION
Cervical cancer, one of the most common gynecological malignancies, poses a serious threat to women's health. According to the World Health Organization, each year, there are more than 500,000 new cases of cervical cancer worldwide and approximately 275,000 deaths due to cervical cancer, the majority of which occur in develop-ing countries [1] . In 2015, 98,900 new cases of cervical cancer were reported in China, making cervical cancer the seventh most common among female cancers and the second most common gynecological cancer. Furthermore, approximately 30,000 people die each year of cervical cancer in China [2] , and Shache County in southern Xinjiang is among the top three regions with the highest cervical cancer mortality. Since the 1970s when German virologist Zur Hausen proposed the hypothesis that human papillomavirus (HPV) is closely related to the incidence of cervical cancer, many studies have shown that HPV infection, especially continuous infection by high-risk HPV, is the primary cause of most cervical precancerous lesions and cervical cancer [3] . Screening for HPV DNA can improve the detection rate of high-grade cervical intraepithelial neoplasia (CIN) and cervical cancer, which is of great significance for the classification of patients with abnormal thin-prep cytology test (TCT) results and for follow-up after treatment of precancerous lesions [4] . However, most HPV infections are asymptomatic and temporary, and most new infections subside within 2 years [5] . In recent years, the combination of TCT and HPV DNA detection has been applied in the screening of cervical lesions and significantly reduced the incidence of cervical cancer. Most temporary cervical infections can be detected by HPV DNA detection, although this method cannot predict the occurrence of high-grade lesions or cervical cancer. Furthermore, despite the high sensitivity of HPV DNA detection in screening for precancerous cervical lesions and cervical cancer, it has poor specificity [6] . Therefore, the progression of cervical lesions cannot be effectively assessed, and repeated detection of HPV within a period of time can induce mental and financial burdens on patients. Many recent research studies have focused on E6 and E7 proteins, the expression products of oncogenes E6 and E7 of HPV and the key carcinogens in cervical cancer [7, 8] . The viral oncogenes E6 and E7 are located in the early coding region of HPV. One study [9] showed that the expression of E6 and E7 is inevitable in precancerous cervical lesions and cervical cancer, and the key factor leading to carcinogenesis is the expression of their products, E6 and E7 proteins. The transcription of their mRNA is necessary for E6 and E7 function. Therefore, the detection of HPV E6/E7 mRNA can be used to evaluate abnormal cervical cell transformation [9, 10] . In 2006, the European Research Organization in Genital Infection and Neoplasia reached a consensus that the detection of HPV E6/E7 mRNA may be the key in cervical cancer screening research [11] . The US Food and Drug Administration (FDA) recently approved a new detection technology, the Aptima HPV Assay, which is currently the only detection method for high-risk HPV E6/E7 mRNA. The Aptima method can be used to detect HPV E6/E7 mRNA of 14 high-risk HPVs (HPV18, 31, 16, 35, 51, 59, 68, 33, 39, 51, 52, 58, and 66) with a high detection efficiency. Some studies confirmed that the Aptima assay has a higher specificity than hybrid capture (HC)-2 and TCT in the diagnostic detection of high-grade cervical lesions and cervical cancer [12, 13] . The method is simple, and the operator only needs to add the sample to the kit and then read the data. However, the application of this method for screening the population has not yet been fully studied thus far, and whether it can be used for cervical cancer screening must be clinically validated in a large sample. In this study, among 6,800 women who were screened for cervical cancer by undergoing cervix examination, TCT, and HPV DNA testing at the Physical Examination Center and Outpatient Clinic of Xinjiang Uiger Municipal People's Hospital from August 2013 to June 2015, 197 women with abnormal cytological or HPV test results were selected for inclusion in this study to undergo HPV E6/E7 mRNA detection, and the results were compared with those of HPV DNA typing test to investigate its utility in screening for cervical lesions. 
MATERIALS AND METHODS

General data
Laboratory tests TCT assay
After exposing the cervix, a sterile brush on a cell sampler was placed on the transitional zone of the cervix and rotated clockwise for 8-10 rotations. The brush head was washed 10 time with preservation solution and then stored in the preservation solution. The diagnostic method was TBS (the Bethesda System) (2001) classification recommended by the National Cancer Institute (NCI) [14] , which describes normal, atypical squamous cells (ASCs), low-grade squamous intraepithelial neoplasia (LSIL), high-grade squamous intraepithelial neoplasia (HSIL), cervical cancer and so on.
HPV DNA detection
Using the special sampling kit of the second-generation hybrid capture (HC-II) from Digene Inc., (United States), specimens were collected from the cervical canal, and the DNA content of the 13 known high-risk HPV DNAs (i.e., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 , and 68) was tested and analyzed by the laboratory physicians. The specimens were first dissolved, and the nucleic acid was melted and denatured to release single-strand HPV DNA. Then, a full-length viral RNA probe was bound to the target DNA of the HPV virus to form an RNA/DNA complex, which was captured by an antibody coated on a microplate that specifically bound to the RNA/DNA complex. Next, the captured complex was bound by the secondary antibody, which was coupled with alkaline phosphatase. The alkaline phosphatase substrate was added to produce a chemiluminescent signal, and the quantity of the target DNA was detected by the luminometer. Finally, the number of copies was calculated, and the DNA with copy numbers greater than 0 were designated positive.
HPV DNA typing test
The HPV typing test was carried out according to the manufacturer's instructions of the HPV typing test kit (Guangdong Hybribio) for typing the 21 kinds of HPV. The main steps included whole genome DNA extraction, polymerase chain reaction (PCR), and flowthrough hybridization. In addition, the results were judged by the naked eye; specifically, the positive points were the clearly visible blue-violet dots on the corresponding positions on the membrane strip's HPV typing distribution map. Normally, samples show blueviolet dots on the PC points on each strip (including the negative control). Negative controls show no blue points on the 21 HPV subtype sites. Positive controls show blue dots on the corresponding sites on the strip but no blue dots on the other subtype sites. If the tested specimens showed blue-purple dots on the 21 subtype positions, the HPV subtype on the corresponding position was determined as positive. One dot represents infection with a single HPV subtype, and two or more dots indicate multiple infections. In addition, each chip has an internal control point (PCR mapping control point) and a biotin control point (hybridization color quality control point).
HPV E6/E7 mRNA detection
The APTIMA HPV test was developed by Gen-Probe USA and approved by the U.S. FDA in 2011. The method includes sample preparation, transcription-mediated amplification, hybridization protection assays and a dual dynamic detection method, and 14 kinds of high risk HPV (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 58, 59, 66, and 68) E6/E7mRNA can be detected. An HPV E6/E7 mRNA Assay Kit was purchased from Haoluojie Medical Technology (Beijing) Co., Ltd. In addition, 2 mL of the remaining TCT solution was used for testing. After the sample solution was centrifuged (3,000 r/min) twice for 5 minutes each, the supernatant was discarded, lysate and proteinase K were added, and the sample was placed in an incubator at a stable temperature of 65°C for approximately 1.5 hours. The samples were removed every 30 minutes and shaken well, and they were then added to a 96-well test plate containing 2 wells that served as blank controls and 2 wells that served as positive controls. The target mRNAs were captured by two capture probes and amplified in 3 steps, and then, a substrate and a substrate catalyst were added. The amplified molecules were hybridized with alkaline phosphatase-labeled probes, and a substrate was added to react with the probe to produce chemiluminescent signals. The signal intensity is positively correlated with the amount of mRNA. The amount of the target mRNA was detected by a luminometer and was calculated according to the number of copies. Copy number > 0 indicates positive; copy number < 4,000 indicates low risk; copy number 4,000 -10,000 indicates medium risk; and copy number > 10,000 indicates high risk.
Histopathological examination
Tissue specimens were obtained by colposcopy biopsy and were fixed with 10% formaldehyde. They were then cut into 1.5 cm x 1.5 cm x 0.3 cm sections and dehydrated for 2 hours each in 80%, 90%, 95%, and 100% ethanol solutions. Xylene was used to dissolve the paraffin, and the samples were embedded, sliced, stained by conventional HE, sealed, and evaluated by pathologists (an associate chief physician or chief physician). Histopathological diagnoses included chronic cervicitis, low-grade CIN (CIN-I), high-grade CIN (CIN II and III) and invasive cervical cancer.
Statistical analysis
The data obtained in this study included qualitative indicators such as ethnicity, family history of cancer, use of an intrauterine device (IUD), previous HPV infection, smoking and passive smoking, which were described by using the constituent ratio and the rate. Comparisons of differences in these qualitative indicators between the high-grade and low-grade lesion groups were performed by using the Chi-square test or Fisher's test. In contrast, quantitative indicators such as age, age of the first sexual activity, number of sexual partners, and number of births were described by using the mean and standard deviation. Comparisons of differences in these quantitative indicators between the high-grade and low-grade lesion groups were performed by using t-tests or the Welch F test. In calculating the accuracy of HPV E6/E7 mRNA detection in the diagnosis of cervical lesions, the ROC curve was first drawn, and the cutoff point was determined; samples with values greater than the zero-point were regarded as positive, and those with values lower than the zero-point were regarded as negative. Then, a four-fold table for diagnostic trials was established to calculate the sensitivity, specificity, positive predictive value, negative predictive value, positive likelihood ratio, negative likelihood ratio, Youden in-dex, pre-test probability, and post-test probability. The accuracy of the HPV DNA test and HPV E6/E7 mRNA detection in the diagnosis of high-grade cervical lesions was determined by parallel or tandem trials and combined with the four-fold table of the diagnostic test to calculate the indicators. The overall test level was 0.05, and the statistical software was SAS JMP10.0.
RESULTS
General data
A total of 197 subjects were included in this study from among 6,800 women who had a cervical screening at the Physical Examination Center or the Outpatient Clinic. The population screening process is shown in Figure  1 . Among the 197 subjects, there were 108 Han and 89 Uighur subjects, with an average age of 45.87 ± 11.82 years, and 101 high-grade lesions and 96 lowgrade lesions.
Relationship between general data and high-grade/ low-grade lesions
The prevalence rate of high-grade cervical lesions among Uighur subjects was 61.80%, which was significantly higher than that of Han subjects (42.59%) (p = 0.007). The average age of the high-grade lesion group (48.82 ± 12.48 years) was significantly higher than that of the low-grade group (42.77 ± 10.28 years); the age of the first sexual activity of the high-grade lesion group (19.54 ± 4.20 years) was significantly lower than that of the low-grade lesion group (22.05 ± 4.14 years); the number of births in the high-grade lesion group (2.95 ± 1.92 births) was significantly greater than that of the low-grade group (1.45 ± 1.09 births) (p < 0.001 for all) ( Table 1) .
HPV E6/E6 mRNA diagnostic receiver operating characteristic (ROC) curve for high-grade lesions and diagnostic results
HPV E6/E6 mRNA levels were quantitated using APTIMA assays. The ROC curve of the 197 patients who underwent HPV E6/E7 mRNA detection for the diagnosis of high-grade lesions is shown in Figure 2 and had an AUC of 0.7495.
The diagnostic results of HPV E6/E7 mRNA detection
The results of the diagnostic test using HPV E6/E7 mRNA detection are shown in Table 2 ; the sensitivity was 85.2% (76.4% -91.2%), the specificity was 66.7% (56.2% -75.8%), the Youden index was 0.518, the positive predictive value was 72.9 (63.8% -80.5%), the negative predictive value was 81.0% (70.3% -88.6%), the positive likelihood ratio was 2.555 (1.903 -3.429), and the negative likelihood ratio was 0.222 (0.138 -0.359). The pre-test probability was 51.3%, and the post-test probability was 72.9%, i.e., according to this study, for a prevalence of 51.3% and an HPV E6/E7 mRNA value higher than 2.10, there was 72.9% certainty of diagnosing the positive patients as high-grade lesions. These results suggest that HPV E6/E7 mRNA detection has satisfactory accuracy when diagnosing highgrade cervical lesions.
The diagnostic results of HPV DNA typing tests
The results of the diagnostic tests performed on the 101 patients who voluntarily underwent HPV DNA typing are shown in Table 3 . The sensitivity was 70.0%, lower than that of the HPV E6/E7 mRNA diagnostic test (85.2%); the specificity was 43.9%, lower than that of the HPV E6/E7 mRNA (66.7%); the Youden index was 0.139, lower than that of the HPV E6/E7 mRNA diagnostic test (0.518); the positive predictive value was 64.6%, lower than that of the E6/E7 mRNA diagnostic test (72.9%); the negative predictive value was 50%, lower than that of the HPV E6/E7 mRNA diagnostic test (81.0%); the positive likelihood ratio was 1.248, lower than that of the HPV E6/E7 mRNA diagnostic test (2.555); the negative likelihood ratio was 0.683 higher than that of the HPV E6/E7 mRNA diagnostic test (0.222); the pre-test probability was 59.4%, and the post-test probability was 64.6%, lower than that of the HPV E6/E7 mRNA diagnostic test (72.9%). These results indicate that HPV E6/E7 mRNA detection is superior to the HPV DNA typing test for the diagnosis of high-grade cervical lesions.
Consistency evaluation of HPV DNA typing and HPV E6/E7 mRNA detection in the diagnosis of cervical lesions
The results of the consistency evaluation of HPV DNA typing and HPV E6/E7 mRNA detection in the diagnosis of high-grade and low-grade cervical lesions are shown in Table 4 . The Kappa value was 0.1998, and the 95% confidence interval (CI) was (0.0057, 0.3938). A Kappa value < 0.4 indicates that HPV DNA typing or HPV E6/E7 mRNA detection alone has poor consistency in diagnosing high-grade cervical lesions.
DISCUSSION
Cervical cancer is the only gynecologic malignancy in the world that can be eliminated by preventive measures. Early cervical precancerous lesions can be blocked from progressing to cervical cancer through early screening and effective interventions. Cervical cancer is caused by infection with high-risk HPV [15] [16] [17] . However, HPV DNA testing is only an etiological test, and HPV is in most cases eliminated by the body's own immune system, so that only a small proportion of persistent high-risk HPV infections progress to cervical cancer. The first internationally approved method for detecting HPV DNA in clinical practice is the HC-2 assay. Ronco et al. summarized the results of randomized controlled trials performed in four European countries (Belgium, Sweden, the Netherlands, and Italy) and com- pared the differences between HPV DNA detection and cytological tests as screening tools for cervical cancer.
In the first round of follow-up (2.5 years), the two screening methods showed a similar effect in detecting invasive cervical cancer, while in longer follow-ups of 3.5 years and 5.5 years, the cumulative incidence of invasive cervical cancer in the HPV-negative subjects was lower than in cytology-negative subjects. This indicates that HPV-based screening methods can predict 60% to 70% more cases of invasive cervical cancer that are predicted by cytological methods and affirms the long-term protection provided by HPV testing [18] . As large-scale clinical studies have confirmed that the HPV-based screening method possesses a high sensitivity and is easy to repeat, this method is currently recognized as the gold standard for clinical HPV testing. However, it has low specificity [19, 20] . Therefore, how to improve the specificity of HPV detection in screening for cervical cancer and avoid over-treatment of patients with positive HPV infection have become major topics of interest. Although HPV E6/E7 mRNA detection has been proposed as a surrogate method for cervical cancer screening [8] [9] [10] [11] , studies with large sample sizes need to be conducted to confirm its accuracy. In addition, HPV phenotypes vary among different ethnic groups [21] . To the best of our knowledge, no previous study has used HPV E6/E7 mRNA detection in Xinjiang, a region with high cervical cancer-related morbidity and mortality. This study detected HPV E6/E7 mRNA in a Xinjiang population for the first time. The results showed that HPV E6/E7 mRNA was expressed in cervicitis, cervical intraepithelial neoplasia, CIN, and cervical cancer. The sensitivity of HPV E6/E7 mRNA detection for the diagnosis of high-grade cervical lesions was 0.8515, the specificity was 0.6667, the positive predictive value was 0.7288, and the negative predictive value was 0.8101. The values of HPV E6/E7 mRNA in different pathological groups differed significantly (p < 0.05). The values of HPV E6/E7 mRNA in the CIN-II/III and cervical cancer groups were significantly higher than those in the CIN-I and inflammatory groups. The positive expression rate of E6/E7 mRNA also gradually increased with the increasing degree of cervical lesions. A previous study found that the positive rate (X2 = 41.396, p < 0.001) and the copy number (H = 39.350, p < 0.001) of HPV E6/E7 mRNA exhibited rising trends with the increase in pathological grade of cervical lesions [18] . There was a significant positive correlation between the results of HPV E6/E7 mRNA detection and HPV E6/E7 DNA detection (r = 0.465, p = 0.002), which indicates that the technique was reliable. This is in accordance with the experimental results reported in this paper. The development of cervical cancer in patients with a high risk of cervical lesions was more accurately predicted by HPV mRNA detection than HPV DNA testing [22] . Thus, HPV E6/E7 mRNA may be an important factor in the canceration of cervical cells. This is mainly because in the early stage of HPV infection, the expression levels of intracellular viral oncogenes are low, but as the course of the disease progresses, intracellular E6/E7 mRNA is extensively transcribed, resulting in high levels of expression of the E6 and E7 oncogenes [23] . Patients with TCT results of low-grade lesions (ASC-US or LSIL) but who test positive for HPV E6/E7 mRNA repeat a cytopathological test after six months or one year. HPV E6/E7 mRNA detection is more reliable in cervical cancer screening and can more accurately identify women at high risk, reduce false-positives and re-duce unnecessary invasive operations and medical expenses [24] . The HPV DNA typing test can detect 14 high-risk types of HPV. The results of this study showed that HPV16 is the main high-risk type of HPV infection in Xinjiang. In the present study, the sensitivity of the HPV DNA typing test in the diagnosis of high-grade cervical lesions was 0.7, while the specificity was 0.4390, the positive predictive value was 0.6462, and the negative predictive value was 0.50. When used to diagnose highgrade lesions, both the sensitivity and specificity of the HPV DNA typing test were lower than those for HPV E6/E7 mRNA detection, indicating that high-risk HPV E6/E7 mRNA detection can ensure that cervical lesions are highly discriminated and that if a diagnosis is missed, the risk is not higher than that indicated by the HPV DNA typing test. In addition, its positive predictive value and negative predictive value were higher than those of the HPV DNA typing test, which ensures its accuracy in determining lesions that have progressed to highrisk lesions. Therefore, HPV E6/E7 mRNA detection has a high diagnostic credibility. Studies have shown that the sensitivity of AHPV (APTIMA HPV, Hologic, qualitative detection of 14 high risk HPV E6/E7 mRNA) is similar to that of HC-2 but its specificity is higher than that of HC-2 and similar to that of cytological tests [25] . However, the detection of HPV E6/E7 mRNA is more expensive and is not suitable for some poor, remote areas in southern Xinjiang. It is also not suitable for the initial screening of cervical cancer. However, in poor, remote places, we recommend a program in which the HPV DNA typing test is used as the first screening measure, followed by testing positive patients with the HPV E6/E7 mRNA detection method, and finally, referring HPV E6/E7 mRNA-positive women to undergo colposcopy biopsies, while other patients are followed up and re-checked after 6 -12 months. Although HPV E6/E7 mRNA detection is expensive, it reduces the number of colposcopy callbacks after initial screening as well as the costs associated with HPV DNA testing and cervical biopsy without adding to the overall cost. Moreover, it can reduce the workload of doctors and the unnecessary interventions in populations with a transient HPV infection. Due to limited research funds, only 197 women with abnormal cytology or HPV test results were included as research subjects. Future studies are being planned to overcome the limitation of the small sample size by the hospital purchasing more equipment and enabling economically capable women to participate in the study.
CONCLUSION
In summary, HPV E6/E7 mRNA detection can be used as a screening tool for cervical cancer. Its combination with cytology and/or HPV DNA detection during screening will not only contribute to improving the accuracy of diagnosing cervical cancer but also play a role in the early diagnosis and treatment of cervical diseases.
